Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · KORU Medical Systems, Inc. (KRMD)

KORU Medical amends manufacturing deal with Command Medical, extends term to 2031

Neutral Impact 3 of 5 product/contract Written later

KORU Medical Systems signed Amendment No. 1 to its manufacturing and supply agreement with Command Medical Products on June 24, 2026, covering subassemblies, needle sets and tubing. The amendment extends the initial term to December 31, 2031, makes Command the exclusive manufacturer of a limited set of products, and requires Command to qualify a second manufacturing site by December 31, 2027, with a termination right for KORU if it does not. The filing discloses no financial figures, so its effect on shareholders' results cannot be measured from this document.

Key points

  • Amendment dated June 24, 2026 modifies the January 1, 2024 agreement with Command Medical Products, LLC.
  • Initial term now expires December 31, 2031, with automatic one-year renewals unless either party gives at least 180 days' notice.
  • Command must obtain and qualify a second manufacturing site by December 31, 2027; KORU may terminate if Command fails and does not cure within 30 days.
  • Amendment also changes pricing and payment terms, establishes Command as exclusive manufacturer of a limited set of products, and removes the non-competition provision.

The filing

CompanyKORU Medical Systems, Inc. (KRMD)
Form8-K, current report
Filed with the SECJun 30, 2026, 4:57 PM ET
Accession number0001161697-26-000139

Items reported: 1.01 Material Definitive Agreement

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.